Why the study?
Does lovastatin added to finasteride improve lower urinary tract symptoms, prostate volume, and PSA in men with BPH?
Does lovastatin added to finasteride improve lower urinary tract symptoms, prostate volume, and PSA in men with BPH?
Short-term lovastatin treatment added to finasteride does not improve IPSS, prostate volume, or PSA in men with BPH.
Answers are grounded in this paper and cite their sources.
Addition of lovastatin to finasteride should not yet change BPH practice; leaves open longer-term or alternative statin effects in randomized trials.
OBJECTIVE: To explore whether or not statins have any impact on the progression of components of benign prostatic hyperplasia (lower urinary tract symptoms severity, prostate volume and serum prostate specific antigen (PSA) when combined with other agents inhibiting growth of prostate cells. MATERIALS AND METHODS: This was a preliminary, clinical study. Eligible patients were aged > 50 yrs, with International Prostate Symptom Score (IPSS) between 9 and 19, total prostate volume (TPV) >40 mL, and serum PSA > 1.5 ng/mL. Patients were divided in two groups: those with and those without lipidemia. After selection, eligible BPH patients with lipidemia (n = 18) were prescribed lovastatin 80 mg daily and finasteride 5 mg daily, while eligible patients without lipidemia (n = 15) were prescribed only finasteride 5 mg daily. IPSS, TPV and serum PSA were evaluated at end point (4 months). RESULTS: There was no difference between the two groups on the primary end point of mean change from baseline in IPSS (p = 0.69), TPV (p = 0.90) and PSA (p = 0.16) after 4 months of treatment. CONCLUSIONS: Short-term lovastatin treatment does not seem to have any effect on IPSS, TPV and PSA in men with prostatic enlargement due to presumed BPH.
No takes yet. Share an insight, caveat, or question.
Stamatiou et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: